Press Releases AstraZeneca PLC

Equities

AZN

GB0009895292

Real-time Estimate Cboe Europe Other stock markets 11:24:13 2024-05-23 am EDT			5-day change	1st Jan Change
12,424 ^GBX	+0.52%		+2.20%	+17.30%

04:02pm	AstraZeneca: licensing agreement signed with Nona Biosciences	CF
06:21am	HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)	07:02am	BU
AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024	May. 22	BU
Astrazeneca looks to double revenue in 'new era of growth'	May. 22	AQ
INSIDE XP POWER REJECTS BID ...	May. 22	AQ
AstraZeneca : Oncology presentation	May. 21	PU
AstraZeneca : Rare Disease presentation	May. 21	PU
AstraZeneca : BioPharmaceuticals presentation	May. 21	PU
AstraZeneca : Investor Day Agenda	May. 21	PU
AstraZeneca : Investor Day Biographies	May. 21	PU
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030	May. 21	BU
Astrazeneca set to build cancer drug plant in Singapore	May. 21	AQ
AstraZeneca announces $1.5b ADC manufacturing facility	May. 20	AQ
Astrazeneca - New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	May. 20	AQ
AstraZeneca : plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore - Form 6-K	May. 20	PU
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease	May. 19	BU
AlzeCure Pharma AB - Eli Lilly's and AstraZeneca's former head of research Dr. Jan Lundberg elected as a new board member	May. 16	AQ
AstraZeneca : SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population - Form 6-K	May. 16	PU
Insights into AstraZeneca's MANDARA Phase III data	May. 16	AQ
Notice to the Annual General Meeting of Cline Scientific AB	May. 16	AQ
AstraZeneca : Transaction by Person Discharging Managerial Responsibilities - Form 6-K	May. 15	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 12:02 pm EDT